Optimising treatment outcomes: a review of current management strategies in first-line chemotherapy of metastatic breast cancer

This publication has 47 references indexed in Scilit:

• Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.
  Journal of Clinical Oncology, 1996
• Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
  Journal of Clinical Oncology, 1995
• Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.
  Journal of Clinical Oncology, 1993
• The influence of chemotherapy on survival after recurrence in breast cancer—a population-based study of patients treated in the 1950s, 1960s and 1970s
  European Journal Of Cancer, 1993
• Treatment of the terminal stages of breast cancer.
  BMJ, 1989
• Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.
  Journal of Clinical Oncology, 1987
• Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment
  Breast Cancer Research and Treatment, 1985
• Cisplatin in the treatment of metastatic breast carcinoma A prospective randomized trial of two dosage schedules
  American Journal of Clinical Oncology, 1982
• Complete Responders to Chemotherapy in Metastatic Breast Cancer
  JAMA, 1979
• Adriamycin versus methotrexate in five-drug combination chemotherapy for advanced breast cancer. A randomized trial
  Cancer, 1978